|
1
|
Danquah MK, Zhang XA and Mahato RI:
Extravasation of polymeric nanomedicines across tumor vasculature.
Adv Drug Deliv Rev. 63:623–639. 2011. View Article : Google Scholar
|
|
2
|
Dewhirst MW, Cao Y and Moeller B: Cycling
hypoxia and free radicals regulate angiogenesis and radiotherapy
response. Nat Rev Cancer. 8:425–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brahimi-Horn MC, Chiche J and Pouysségur
J: Hypoxia and cancer. J Mol Med Berl. 85:1301–1307. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar :
|
|
5
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl
Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar
|
|
7
|
Jaakkola P, Mole DR, Tian YM, Wilson MI,
Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji
M, Schofield CJ, et al: Targeting of HIF-alpha to the von
Hippel-Lindau ubiquitylation complex by O2-regulated
prolyl hydroxylation. Science. 292:468–472. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang GL and Semenza GL: Purification and
characterization of hypoxia-inducible factor 1. J Biol Chem.
270:1230–1237. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rankin EB and Giaccia AJ: The role of
hypoxia-inducible factors in tumorigenesis. Cell Death Differ.
15:678–685. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsuzuki Y, Fukumura D, Oosthuyse B, Koike
C, Carmeliet P and Jain RK: Vascular endothelial growth factor
(VEGF) modulation by targeting hypoxia-inducible
factor-1alpha--> hypoxia response element--> VEGF cascade
differentially regulates vascular response and growth rate in
tumors. Cancer Res. 60:6248–6252. 2000.PubMed/NCBI
|
|
11
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim BW, Koppula S, Kim IS, Lim HW, Hong
SM, Han SD, Hwang BY and Choi DK: Anti-neuroinflammatory activity
of Kamebakaurin from Isodon japonicus via inhibition of c-Jun
NH(2)-terminal kinase and p38 mitogen-activated protein kinase
pathway in activated microglial cells. J Pharmacol Sci.
116:296–308. 2011. View Article : Google Scholar
|
|
13
|
Lee JH, Choi JK, Noh MS, Hwang BY, Hong YS
and Lee JJ: Anti-inflammatory effect of kamebakaurin in in vivo
animal models. Planta Med. 70:526–530. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hervouet E, Cízková A, Demont J,
Vojtísková A, Pecina P, Franssen-van Hal NL, Keijer J, Simonnet H,
Ivánek R, Kmoch S, et al: HIF and reactive oxygen species regulate
oxidative phosphorylation in cancer. Carcinogenesis. 29:1528–1537.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai XF, Jin X, Lee D, Yang YT, Lee K, Hong
YS, Lee JH and Lee JJ: Phenanthroquinolizidine alkaloids from the
roots of Boehmeria pannosa potently inhibit hypoxia-inducible
factor-1 in AGS human gastric cancer cells. J Nat Prod.
69:1095–1097. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li L, Dai HJ, Ye M, Wang SL, Xiao XJ,
Zheng J, Chen HY, Luo YH and Liu J: Lycorine induces cell-cycle
arrest in the G0/G1 phase in K562 cells via HDAC inhibition. Cancer
Cell Int. 12:492012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vaupel P and Mayer A: Hypoxia in cancer:
Significance and impact on clinical outcome. Cancer Metastasis Rev.
26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Obermair A, Bancher-Todesca D, Bilgi S,
Kaider A, Kohlberger P, Müllauer-Ertl S, Leodolter S and Gitsch G:
Correlation of vascular endothelial growth factor expression and
microvessel density in cervical intraepithelial neoplasia. J Natl
Cancer Inst. 89:1212–1217. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tseng PL, Tai MH, Huang CC, Wang CC, Lin
JW, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, et al: Overexpression
of VEGF is associated with positive p53 immunostaining in
hepato-cellular carcinoma (HCC) and adverse outcome of HCC
patients. J Surg Oncol. 98:349–357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maxwell PH, Dachs GU, Gleadle JM, Nicholls
LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW and Ratcliffe PJ:
Hypoxia-inducible factor-1 modulates gene expression in solid
tumors and influences both angiogenesis and tumor growth. Proc Natl
Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Denis N, Kitzis A, Kruh J, Dautry F and
Corcos D: Stimulation of methotrexate resistance and dihydrofolate
reductase gene amplification by c-myc. Oncogene. 6:1453–1457.
1991.PubMed/NCBI
|
